Tele-Rehabilitation Interventions through University-based Medicine for Prevention and Health
TRAUMATIC BRAIN INJURY GUIDELINES
TRAUMATIC BRAIN INJURY GUIDELINES 2020
35. Effie Chew, MD; Ross D. Zafonte, DO, Pharmacological management of
neurobehavioral disorders following traumatic brain injury—A state-of-the-art review.
Journal of Rehabilitation Research & Development. 2009; 46(6), 851–878.
36. Azouvi P, Jokic C, Attal N, Denys P, Markabi S, Bussel B. Carbamazepine in
agitation and aggressive behaviour following severe closed-head injury: Results of an
open trial. Brain Inj. 1999;13(10):797–804.
37. P. Chatham-Showalter, Carbamazepine for combativeness in acute traumatic brain
injury, J Neuropsychiatry. 1996; 8(1), 96–99.
38. Nejad, SH, et al The Use of Antiepileptic Drugs in Acute Neuropsychiatric
Conditions: Focus on Traumatic Brain Injury, Pain, and Alcohol Withdrawal.
International Journal of Clinical Medicine. 2014; 5, 724-736
39. Childers, M.K. and Holland, D. Psychomotor Agitation Following Gabapentin Use in
Brain Injury. Brain Injury, 1997; 11, 537-540.
40. Helmstaedter, C., Fritz, N.E., Kockelmann, E., Kosanetzky, N. and Elger, C.E.
Positive and Negative Psychotropic Effects of Levetiracetam. Epilepsy & Behavior.
2008; 13, 535-541.
41. Smith Jr., K.R., Goulding, P.M., Wilderman, D., Goldfader, P.R., Holterman-
Hommes, P. and Wei, F.F. Neurobehavioral Effects of Phenytoin and Carbamazepine in
Patients Recovering from Brain Trauma: A Comparative Study. JAMA Neurology. 1994;
51, 653-660.
42. Tang, V., Warden, J., Cullen, N. and Rutledge, E. Topiramate in Traumatic Brain
Injury: Adverse Effects on Cognitive Function. Journal of Head Trauma Rehabilitation.
2007; 22, 409-410.
43. Hammond, F., et al. Effectiveness of Amantadine Hydrochloride in the Reduction of
Chronic Traumatic Brain Injury Irritability and Aggression. J Head Trauma Rehab. 2014;
Sept/Oct; 29(5):391-399
44. Leone. H, Polsonetti BW. Amantadine for traumatic brain injury: does it improve
cognition and reduce agitation. Journal of Clinical Pharmacy and Therapeutics. 2005;
30, 101-104.
45. Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in
brain injury rehabilitation. Brain Inj. 1994;8(8):709–18.
46. D. Karli, D. Burke, H. Kim, R. Calvanio, M. Fitzpatrick, D. Temple, M. Macneil, K.
Pesez and P. Lepak, Effects of dopaminergic combination therapy for frontal lobe
dysfunction in traumatic brain injury, Brain Inj. 1999; 13(1), 63–68.
47. L. Cowell and R. Cohen, Amantadine: a potential adjuvant therapy following
traumatic brain injury, J Head Trauma Rehabi. 1995; 10(6), 91–94.
48. Fugate, L.P., Spacek, L.A., Kresty, L.A., Levy, C.E., Johnson, J.C. and Mysiw, W.J.
Measurement and Treatment of Agitation Following Traumatic Brain Injury: II. A Survey
of the Brain Injury Special Interest Group of the American Academy of Physical
Medicine and Rehabilitation. Archives of Physical Medicine and Rehabilitation. 1997;
78, 924-928.
49. C. Gualtieri, Buspirone: Neuropsychiatric effects, J Head Trauma Rehabil. 1991; 6(1)
90–92. 50. BrainLine, 23 Aug. 2020,
www.brainline.org/.
51. Teng C, Bhalerao S, Lee A, et al. The use of buproprion in the treatment of
restlessness after a traumatic brain injury. Brain Inj 2001;15:463-467.